Rona Therapeutics grants Roche exclusive worldwide license for ALK7-targeting RNAi therapy
Rona Therapeutics announced it has granted Roche an exclusive worldwide license for its investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7). The agreement gives Rona up to $100 million in upfront and near-term milestone payments and up to $1.06 billion in potential development, regulatory and commercial milestone payments, plus tiered royalties on global net sales.
Primary source
Company press release (PR Newswire), October 13, 2026
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
Machine-summarized from the source above; not independently reported. How we use automation